CardioMEMS heart pressure monitor study in Medicare patients
Part of Heart & circulation clinical trials.
This study looks at how well the CardioMEMS heart pressure monitor works for people with heart failure who are on Medicare. It gathers real-world information to see if the sensor helps improve health outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a CardioMEMS sensor already implanted in your pulmonary artery.
- You live in the United States.
- Your heart failure symptoms were either Class II or Class III (mild to moderate) when the sensor was placed.
- You are enrolled in Medicare Part A and B (not Part C) now and have been for at least the past year.
- You were at least 18 years old when you got the CardioMEMS sensor.
- You did not have a heart transplant or a mechanical heart pump before getting the sensor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a wearable home monitoring system (myCordella™) can help people with moderate heart failure (NYHA class II or III) by tracking heart pressure and supporting follow-up care. It may help detect changes earlier so clinicians can adjust treatment sooner.
This study tests whether using two implanted devices (CardioMems and BaroStim) can improve heart function and symptoms in people with advanced heart failure. It aims to help patients who are already on standard medications get even better results.
This trial tests whether remote monitoring of your implanted heart device can help your doctors better manage your heart failure. It is for people with certain types of pacemakers or defibrillators who are willing to share their device data remotely.
This study is looking at how well the CardioMEMS heart monitor works for people with heart failure. The device is already implanted and tracks pressure in your lung artery to help your doctor manage your condition and potentially prevent hospital visits.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This study checks how safe a small heart-pressure monitoring device is for people with advanced heart failure and severe kidney problems. It looks at whether doctors can continuously track heart filling/pressure to help manage symptoms and reduce risks.
Hear when a new Heart Failure NYHA Class II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.